Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics announced that CEO David Stamler will participate in a fireside chat at the Craig-Hallum Virtual B | Oct 19, 2026 |
| BLTE | 6-K | neutral | 4/10 | Belite Bio announced it has received approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Globa | Oct 19, 2026 |
| EVAX | 6-K | bullish | 6/10 | Evaxion reported that all patients in the phase 2 trial of personalized cancer vaccine EVX-01 maintained clinical respon | Oct 19, 2026 |
| DCOY | EFFECT | neutral | 4/10 | The SEC declared effective the S-1 registration statement (File No. 333-299353) for Decoy Therapeutics Inc. on October 1 | Oct 19, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $558K in open-market shares on October 15-16, 2026. The sales f | Oct 18, 2026 |
| ZNTL | PRESS-RELEASE | bullish | 7/10 | Zentalis announced positive overall survival data from an interim analysis of the DENALI Part 1b study for azenosertib i | Oct 18, 2026 |
| IRON | PRESS-RELEASE | mixed | 7/10 | Disc Medicine announced a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in er | Oct 18, 2026 |
| ALXO | SC 13D/A | neutral | 4/10 | venBio Global Strategic Fund, L.P. filed Amendment No. 2 to its Schedule 13D on ALX Oncology Holdings Inc., reporting an | Oct 16, 2026 |
| LODE | SC 13D/A | bearish | 6/10 | MAK Capital Fund LP filed Amendment No. 2 to its Schedule 13D, reporting a reduction in its beneficial ownership of Coms | Oct 16, 2026 |
| ANIP | CLUSTER | bearish | 4/10 | Two ANIP insiders, including the CEO, sold a total of $425K in open-market sales over a week. The CEO's $388K sale is th | Oct 16, 2026 |
| TARS | INST-CLUSTER | bullish | 4/10 | Three institutional buyers added $15.2M in TARS positions during Q3 2026, led by Wasatch Advisors doubling down with a $ | Oct 16, 2026 |
| ABBV | INST-CLUSTER | bullish | 4/10 | Three institutional asset managers added or doubled their AbbVie positions in Q3 2026, with aggregate buying of $120.3M | Oct 16, 2026 |
| ZTS | INST-CLUSTER | bullish | 4/10 | Three asset managers accumulated $10.0M in Zoetis shares during Q3 2026, led by Wealth Enhancement Advisory Services dou | Oct 16, 2026 |
| VRTX | INST-CLUSTER | bullish | 4/10 | Three asset managers added to their VRTX positions in Q3 2026, led by a $260M increase from Assenagon Asset Management, | Oct 16, 2026 |
| LLY | INST-CLUSTER | bullish | 4/10 | Five asset managers added $406.3M to their LLY positions in Q3 2026, led by Assenagon Asset Management's $307.3M increas | Oct 16, 2026 |
| OLMA | SC 13D/A | neutral | 2/10 | Biotechnology Value Fund (BVF) filed an amended Schedule 13D reporting that Dr. Gorjan Hrustanovic resigned from Olema's | Oct 16, 2026 |
| CRSP | CLUSTER | neutral | 3/10 | Three CRSP insiders, including the CEO and a director, sold a combined ~$973K in open-market sales over a two-day window | Oct 16, 2026 |
| CRSP | CLUSTER | bearish | 4/10 | Three CRISPR Therapeutics insiders, including the CEO and General Counsel, sold a total of ~$973K in open-market sales o | Oct 16, 2026 |
| RTSN | SC 13G | neutral | 4/10 | B Group, Inc., B Group Capital LLC, and Branden B. Muhl filed a Schedule 13G disclosing passive beneficial ownership of | Oct 16, 2026 |
| PTCT | CLUSTER | neutral | 3/10 | Two PTCT insiders, a director and the EVP & CLO, sold a combined $138K in shares over a one-week window. The sales are s | Oct 16, 2026 |
| ADIL | DEFA14A | bearish | 5/10 | Adial Pharmaceuticals filed a DEFA14A to announce a further adjournment of its 2026 Annual Meeting for Proposals 3, 4, 5 | Oct 16, 2026 |
| NRXP | 8-K | neutral | 2/10 | NRx Pharmaceuticals filed an 8-K to announce the 2026 Annual Meeting of Stockholders, scheduled for December 17, 2026, w | Oct 16, 2026 |
| ADIL | 8-K | bearish | 5/10 | Adial Pharmaceuticals further adjourned its 2026 Annual Meeting for the fourth time, from October 15 to October 26, 2026 | Oct 16, 2026 |
| SAFX | SC 13D/A | bullish | 7/10 | EEME Energy SPV I, LLC and its managing member Majique Ladnier filed an amended Schedule 13D disclosing a significant st | Oct 16, 2026 |
| IAM | 8-K | neutral | 2/10 | Iambic Therapeutics filed an 8-K on October 16, 2026, reporting the adoption of amended and restated certificate of inco | Oct 16, 2026 |
| BMRA | DEF 14A | neutral | 4/10 | Biomerica's 2026 definitive proxy statement schedules its annual meeting for December 11, 2026, with five proposals: ele | Oct 16, 2026 |
| MPLT | CLUSTER | bearish | 4/10 | CEO Christopher Kroeger and CAO/Interim CFO Jonathan Gillis sold a combined $678K in open-market sales on October 15, 20 | Oct 16, 2026 |
| HURA | 8-K | neutral | 2/10 | TuHURA Biosciences drew an additional $650,000 under its existing $50 million revolving credit facility with Parkview Ho | Oct 16, 2026 |
| PMCB | 8-K | bearish | 5/10 | PharmaCyte Biotech dismissed its auditor, CBIZ CPAs, and engaged Grassi & Co. as its new independent registered public a | Oct 16, 2026 |
| CBIH | NT 10-Q | bearish | 7/10 | Cannabis Bioscience International Holdings, Inc. (CBIH) filed a late notification (NT 10-Q) for its quarterly report for | Oct 16, 2026 |